BioClinica®, Inc. has announced that Europe was the fastest growing geographic region in 2013 for its eClinical technology products. The Company plans continued investments in its European workforce in the areas of operations and sales, potentially doubling its European eClinical presence in 2014.
The growing team supports BioClinica's full suite of eClinical offerings, including CTMS, EDC, IRT, and clinical supplies planning. Currently, the Company has employees in corporate offices in Lyon, France; Leiden, The Netherlands; and Munich, Germany, with additional personnel in Switzerland, Belgium and the United Kingdom.
According to Martijn Princen, BioClinica's Head of European eClinical Sales, "One of the pillars for success in this or any geographic market essentially is the eClinical technology itself. With a web-based, easy-to-use platform, supported by experienced people on the ground here in Europe, more and more companies are selecting BioClinica for both European and global studies."
BioClinica's diverse European customer base includes Pharmaceutical, Biotechnology and Medical Device companies, with CROs and mid-market organizations comprising the largest new market share.
Several industry-leading companies will participate in BioClinica's first European User Conference to be held in Cologne, Germany on 26 February which will feature presentations from companies such as Johnson & Johnson, Nestlé, Grünenthal, Sanofi, Biosense Webster, TauRx, and Cerbomed.
BioClinica Technology Partner NNIT will lead a session on SharePoint implementation, systems integration, and validation. The European User Conference will be held at the Microsoft Executive Briefing Center in Cologne, a fitting location as BioClinica is an elite member of Microsoft's Partner Network.
"In terms of innovation, OnPoint CTMS and Trident IRT have been the big attention-getters, driven by the need for better speed and flexibility that is central to clinical research. For example, a CTMS needs to grow with an organization and have capacity to manage complex clinical trials long-term," Princen explains and adds, "Now the trend is for large and mid-size Sponsors and CROs to replace their existing CTMS with a more sophisticated end-to-end clinical trial management solution."
Such is the case with Mundipharma, a dynamic pharmaceutical research and development company that has selected BioClinica's OnPoint CTMS for various aspects of its clinical trial management activity. "The industry has been searching for a more innovative approach to managing the dynamics of running international studies, and BioClinica is filling that need," Princen says. "As for growing CROs, OnPoint CTMS enables them to more efficiently manage studies for a rapidly expanding client base and on a global scale."
Aside from tremendous CTMS growth, BioClinica is experiencing increased demand for IRT and EDC solutions, particularly by CROs. This comes on the heels of several major IRT and EDC implementations, including one study with 17,000 subjects and 442 sites in 17 countries. "Our success supporting global studies like this drives even greater interest in our technologies," Princen says.